CINGW — Cingulate Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1862150 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -7,923,318 | -9,312,089 | 30,861,701 | 25,893,210 | 11,996,835 |
| Dec 2025 | 0 | — | -5,585,948 | -6,272,910 | 15,073,263 | 10,953,383 | 12,564,356 |
| Sep 2025 | 0 | — | -5,995,544 | -7,341,062 | 10,518,892 | 6,118,710 | 7,045,206 |
| Jun 2025 | 0 | — | -4,649,939 | -4,788,735 | 13,468,208 | 8,900,183 | 7,956,334 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,549,860
Investing CF
$-223,321
Financing CF
$36,147,425
CapEx
$-415,858
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-141,687,120
Inventory
—
Receivables
$53,938
ST Investments
—
EBIT TTM
$-24,154,749
Pretax Income TTM
$-27,714,796
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,938,057 | -22,449,911 | 15,073,263 | 12,564,356 | — | -17,245,182 |
| Dec 2024 | 0 | -15,645,265 | -16,559,605 | 14,864,489 | 7,408,984 | — | -18,451,387 |
| Dec 2023 | 0 | -22,759,304 | -23,534,947 | 3,491,436 | 10,360,865 | — | -15,034,543 |
| Dec 2022 | 0 | -17,502,280 | -17,676,232 | 11,405,057 | 7,523,035 | — | -15,882,808 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $991.62B | $1112.00 | — |
| JNJ | JOHNSON & JOHNSON | $563.77B | $234.20 | — |
| ABBV | AbbVie Inc. | $390.87B | $221.23 | — |
| NVS | NOVARTIS AG | $287.89B | $150.88 | — |
| MRK | Merck & Co., Inc. | $285.12B | $115.44 | — |
News headlines (Yahoo Finance, 1h cache)
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
2026-06-16 12:00 · Yahoo
Cingulate Receives Complete Response Letter from FDA for CTx-1301
2026-06-02 12:00 · Yahoo
CING: Building Its Cash Position
2026-05-19 09:25 · Yahoo
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
2026-05-14 12:00 · Yahoo
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
2026-04-24 19:03 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
2026-04-06 20:34 · Yahoo
CING: Laying the Foundation for 1H:27 Launch
2026-03-20 11:50 · Yahoo
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
2026-03-18 12:00 · Yahoo
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-13 13:00 · Yahoo
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
2025-11-10 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.